Market Overview

Morgan Stanley Upgrades Boston Scientific on Pipeline Acceleration

Related BSX
Earnings Scheduled For February 1, 2018
Boston Scientific's Millipede Deal To Aid MR Business

In a report published Monday, Morgan Stanley analyst David Lewis upgraded Boston Scientific (NYSE: BSX) from Equal-weight to Overweight based on pipeline acceleration traction.

Despite disappointing pipeline progress in 2013 from Asthmatx reimbursement delays and S-ICD manufacturing constraints, Morgan Stanley expects sales results to improve. Morgan Stanley's updated model shows risk-adjusted pipeline sales of $90 million (130 bps) in 2014 and $145 million (180 bps) in 2015, which drives a $0.07 (8%) EPS accretion by 2015.

Lewis reported that Boston Scientific has the best opportunity for margin improvements in cardiology. The analyst commented, “At 19%, cash operating margins are depressed relative to peers. In particular, CRM margins of 12-13% are half those of competitors; normalizing CRM profitability alone could drive 15%+ upside to EPS over several years. Structural cost programs have done an impressive job of supporting the P&L during a multi-year contraction in revenue, but margin results should accelerate in a more visible way as revenue growth rates push into the mid single digits and drive much better leverage over a fully-loaded expense structure.”

Shares of Boston Scientific Corporation closed at $11.93 on Friday and is currently trading at $12.28, up 2.93%.

Latest Ratings for BSX

Jan 2018RBC CapitalUpgradesOutperformTop Pick
Jan 2018Evercore ISI GroupInitiates Coverage OnIn-Line
Dec 2017NeedhamUpgradesBuyStrong Buy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: David Lewis Morgan StanleyAnalyst Color Upgrades Analyst Ratings


Related Articles (BSX)

View Comments and Join the Discussion!